StockDriftsStockDriftsTop 14 Decheng Capital LLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| CGON | CG ONCOLOGY INC | 61.87% | 6.37M | $452.7M | +0.00%(+0) | $42.37(+79.08%) | 2026-06-30 | |
| NUVB | Nuvation Bio Inc. | 20.15% | 25.95M | $147.4M | +0.00%(+0) | $2.80(+124.29%) | 2026-06-30 | |
| AARD | AARDVARK THERAPEUTICS INC | 3.08% | 3.92M | $22.6M | +0.00%(+0) | $7.51(-14.65%) | 2026-06-30 | |
| ACRS | Aclaris Therapeutics, Inc. | 2.92% | 4.04M | $21.4M | +0.00%(+0) | $1.90(+208.67%) | 2026-06-30 | |
| UPB | Upstream Bio Inc. | 2.58% | 2.72M | $18.9M | +0.00%(+0) | $16.44(-57.85%) | 2026-06-30 | |
| RCUS | Arcus Biosciences, Inc | 1.96% | 464.8K | $14.3M | -2.73%(-13.04K) | $13.11(+120.19%) | 2026-06-30 | |
| EQ | Equillium Inc. | 1.94% | 4.45M | $14.2M | +0.00%(+0) | $0.73(+175.34%) | 2026-06-30 | |
| RVMD | REVOLUTION MEDICINES INC(NSM) | 1.35% | 52.7K | $9.9M | -43.67%(-40.83K) | $44.52(+353.70%) | 2026-06-30 | |
| LYEL | Lyell Immunopharma, Inc. | 1.33% | 692.0K | $9.7M | +0.00%(+0) | $20.66(-32.15%) | 2026-06-30 | |
| BYSI | BeyondSpring Inc. | 0.91% | 3.80M | $6.7M | +0.00%(+0) | $0.85(-0.45%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (10 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | +23.94% |
| Top 20 Holdings Unweighted | — | — | — | — | +163.49% |
Decheng Capital LLC reports $731.75M in US-listed equity holdings across 14 positions in its most recent 13F filing. Its largest disclosed positions are CGON (61.9%), NUVB (20.1%) and AARD (3.1%). The top 20 holdings account for 100.01% of reported assets. Its disclosed equity book has returned +23.94% cumulatively over 10 quarters. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Decheng Capital LLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Decheng Capital LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 2010850). View Decheng Capital LLC’s 13F filings on SEC